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Abstract
The 14-3-3 proteins are a set of highly conserved scaffolding proteins that have been implicated in the regulation of a
variety of important cellular processes such as the cell cycle, apoptosis and mitogenic signaling. Recent evidence indicates
that the expression of some of the family members is elevated in human cancers suggesting that they may play a role in
tumorigenesis. In the present study, the oncogenic potential of 14-3-3c was shown by focus formation and tumor formation
in SCID mice using 14-3-3c transfected NIH3T3 mouse fibroblast cells. In contrast, 14-3-3s, a putative tumor suppressor,
inhibited NIH3T3 transformation by H-ras and c-myc. We also report that activation of both MAP kinase and PI3K signaling
pathways are essential for transformation by 14-3-3c. In addition, we found that 14-3-3c interacts with phosphatidylinositol
3-kinase (PI3K) and TSC2 proteins indicating that it could stimulate PI3K signaling by acting at two points in the signaling
pathway. Overall, our studies establish 14-3-3c as an oncogene and implicate MAPK and PI3K signaling as important for 14-
3-3c induced transformation.
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Introduction
14-3-3 proteins are a family of highly conserved proteins that
interact with and regulate a diverse array of cellular proteins.
Seven family members have been identified in mammalian cells
and each is designated by a Greek letter (b, c, e, g, s, t (h) and f).
Interaction between 14-3-3 proteins and their client proteins is
mediated primarily, but not exclusively, through phosphoserine-
binding via a consensus motif that can be phosphorylated by serine
and threonine kinases [1]. As a consequence of this, 14-3-3
proteins are involved in a wide variety of signal regulated cellular
processes [2] including receptor-mediated signal transduction [3],
apoptosis [4], cell cycle progression [5] and checkpoint activation
[6]. Many of the pathways regulated by 14-3-3 proteins become
aberrantly activated during tumorigenesis. Not unexpectedly,
there is mounting evidence that 14-3-3 proteins play a role in
the development of human tumors [7]. This notion is most
compellingly supported by studies which show that the expression
of one family member, 14-3-3s, is down regulated in breast
cancers [8] and it also acts as a tumor suppressor [9]. On the other
hand, 14-3-3f has been shown to cooperate with the Erb2 receptor
to induce epithelial mesenchymal transformation in breast cancer
suggesting that this family member is oncogenic [10]. Moreover,
we and others have shown that 14-3-3 expression is aberrantly up
regulated in several tumor types including lung cancer [11,12,13].
This suggests that abnormal expression of these proteins have a
role in cancer; however, the mechanism by which these proteins
promote neoplastic progression is not well understood.
Here we have focused our attention on 14-3-3c because it is one
of the several 14-3-3 proteins that is up regulated in non small cell
lung cancer and also because it was shown previously that it can
indirectly down regulate the transactivation of p53 tumor
suppressor [14]. Using focus formation assays, we show that 14-
3-3c is an oncogene and that it functions by activating the MAPK
and PI3K pathways. 14-3-3s, in contrast, suppresses focus
formation and inhibits activation of both of these signaling
pathways.
Materials and Methods
Cell Culture and Transfection Conditions
NIH3T3 cell line was obtained from ATCC (American Type
Tissue Culture) and MEF cells were provided by Dr. Thomas
Doetschman, BIO5 Institute, University of Arizona, and these cells
were routinely grown in Dulbecco’s modified minimal essential
medium (Cellgro, VA) supplemented with 2 mM L-glutamine,
nonessential amino acids, 100 U of penicillin, 100 mgo f
streptomycin, and 6–10% fetal calf serum and maintained in a
humidified atmosphere of 5% CO2.
Plasmids
The T24-C3 (activated H-ras inserted into pBR322 plasmid)
vector was obtained from Dr. Barbacid, NIH, MD, USA.
pCMV6-c-myc and pCMV-14-3-3c Flag vectors are laboratory
stocks. The 14-3-3s construct (Gene accession No. AFO29082)
was made by PCR amplification of 14-3-3s cDNA and sub-
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EcoRI fragment of 14-3-3s DNA was finally ligated into the
pCMV-Flag-2b expression vector (Strategene, CA).
Transformation assay
Transformation of NIH3T3 cells was performed according to
the method as described earlier [15]. Briefly, early passages of
NIH3T3 and MEF cells were plated in 30 mm, 6-well plates at a
density of 1610
5cells/well. For transfection, 5–10 mg of each
plasmid was used with LipoTAXI transfection agent (Strategene,
CA). After 48 h, the transfected cells were trypsinized and plated
onto 100 mm plates. Cells were kept in DMEM with 6% calf
serum; the medium was changed every 3–4 days. After 21 days,
cells were stained with 0.005% crystal violet solution and foci
counted using a colony counter.
Soft agar assay
Randomly selected transformed cell colonies were tested in
triplicates for anchorage-independent growth in soft agar by
previously described procedure [16]. To determine colony
forming efficiency, 1610
3 cells were plated in 35 mm dishes.
Fresh liquid medium (0.2 ml) was layered over the surface once a
week to prevent desiccation. After three weeks, the colonies were
stained with INT (2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-phenylte-
trazolium chloride, Sigma Aldrich, MO) and the number of large
colonies (0.1 mm in diameter) with dense centers were counted.
Tumorgenicity in SCID mice
SCID mice were obtained from the University of Arizona SCID
resource. Mice were housed in micro isolator cages and provided
with sterile food and water and treated following the conditions
approved by the Institutional Animal Care and Use Committee for
animal experiments, (Approval Number #09-076). To assess tumor
formationinvivo, 14-3-3c transformed cells(1610
7 cells permouse)
were implanted subcutaneously into the flanks of SCID mice.
Tumor formation was assessed every 3–4 days for a total of 25 days.
Raf-1 assay
Raf-1 immunoprecipitations and kinase assays were performed
as described earlier [17]. Transfected NIH3T3 cells were grown
for two days, and then starved overnight, PBS-washed and lysed
with RIPA buffer and the lysate cleared by centrifugation at
10,000 g (10 min at 4uC). 200 mg of the protein lysate was added
to 2 mg monoclonal anti-Raf-1 antibody (Cell Signaling Technol-
ogy, MA) prebound to 30 ml of protein A/G-agarose beads
(Pierce, IL) and incubated for 1 h at 4uC on a slow rotator. The
Raf-1 immunocomplex was washed three times in ice-cold RIPA
buffer, once in ice-cold washing buffer containing 10 mM HEPES
(pH 7.4), 100 mM NaCl, 20 mg/ml aprotinin and 0.5% NP-40,
and once in ice-cold reaction buffer containing 20 mM Tris
(pH 7.4), 20 mM NaCl, 1 mM DTT and 10 mM MgCl2. Half of
the immunocomplex was used for the kinase reaction and the
other half for the Raf-1 immunoblot. The kinase reaction was
performed in the presence of 20 mM ATP and 500 ng of
recombinant MEK-1 substrate (Upstate, MA), in a total volume
of 40 ml of reaction buffer at 30uC for 30 min with gentle
agitation. Raf-1 immunocomplex was added to the reaction
mixture containing kinase reaction buffer (25 mM HEPES,
pH 7.4; 25 mM glycerol phosphate; 1 mM dithiothreitol;
10 mM manganese chloride; 100 mM ATP and 10 mCi of
[c-
32P] ATP (Perkin Elmer, MA). The reaction was terminated
by the addition of 40 ml2 6SDS sample buffer followed by boiling
for 5 min. Samples were resolved by SDS-PAGE gel. Gels were
fixed, dried and quantified using a Molecular Phosphorimager
(Amersham Biosciences, NJ).
ERK assay
ERK assay was performed as described earlier [18]. Briefly,
transiently transfected NIH3T3 cells were starved overnight,
washed with phosphate buffered saline and 200 mg protein
samples were combined with ERK2 antibody (Santa cruz, CA)
and incubated at 4uC for 4 h with gentle rocking, followed by an
additional 1 h incubation with protein A/G (Pierce, IL). The
pellets were then washed and resuspended with 50 ml kinase buffer
supplemented with 200 mM ATP and 2 mg Elk-1 fusion protein
(Cell Signalling, MA), and incubated at room temperature for
45 min. The reaction was stopped by adding lysis buffer and the
proteins separated by SDS-10% PAGE. After immunoblotting
with rabbit antiphospho- Elk-1 antibody (Cell Signalling, MA), the
blot was stripped with anti-ERK2 (Rabbit polyclonal, Santa Cruz,
CA) to confirm equal loading. Each experiment was repeated
three times and quantified.
PI3K assay
After transient transfection, cell-free lysates were prepared as
described and PI3K assays performed by a previously described
[19] method, in which cells were lysed in the presence of protease
inhibitors. After normalization for protein content, the cleared
lysates were incubated with p110-PI3K antibody (Santa Cruz, CA)
for 2 h at 4uC, followed by addition of protein A/G-agarose beads
(Pierce, IL) and an additional 1 h incubation. The immunopre-
cipitates were then washed three times, as described previously.
The kinase reactions contained 20 mM Tris-HCl, pH 7.6, 75 mM
NaCl, 10 mM MgCl2, 2.5 mM EGTA, 0.2 mg/ml phosphatidy-
linositol, 0.3 mg of phosphatidylserine, 20 mM ATP, 10 mCi of
[c-
32P] ATP and were carried out at room temperature for 10 min
and then stopped with 100 ml of 1 N HCl. Phospholipids were
extracted twice, first with 200 ml of CHCl3:MeOH (1:1) and then
with 160 ml of 1 N HCl:MeOH (1:1), after which the organic
phase was dried and resuspended in 50 ml of CHCl3:MeOH (1:1).
Phosphorylated products were resolved on oxalate impregnated
Silica gel-60 plates (Merck, NJ) using CHCl3:MeOH:Acetone:E-
tOH:H2O (73:48:20:20:19) as solvent. Phosphatidylinositol 3-
kinase activity was determined by autoradiography and quantified
using a Phosphorimager (Amersham Biosciences, NJ).
Immunoprecipitation
For co-immunoprecipitation experiments using lysates from
cells stably expressing 14-3-3c and 14-3-3s proteins, 1 mg of
lysate was mixed with 5 mg of anti-Flag antibody (Sigma Aldrich,
MO), and incubated at 4uC overnight. Then, 30 mL of protein A/
G beads (Pierce, IL) were added to each sample and shaken for
2 h. The beads were then washed three times with RIPA buffer
and resuspended in 30 mlo f2 6SDS-PAGE loading buffer and the
samples were ran on a gel and immunoblotted with the antibodies
noted in the results.
GST-pull down and in vitro kinase assays
All 14-3-3 recombinant proteins were expressed in BL21 E. coli
strain. GST-14-3-3 proteins were purified using glutathione-
Sepharose 4B resin (Amersham Biosciences, NJ), according to
the manufacturer’s instructions. Purified proteins were tested for
purity by gel electrophoresis and Coomassie blue staining. For in
vitro kinase assays, the indicated amount of recombinant GST-14-
3-3 protein was mixed with immunoprecipitates of Raf-1 and
PI3K beads, incubated at 37uC for 2 h, and the kinase assay
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14-3-3 bound beads were incubated with precleared NIH3T3 cell
lysates for 2 h at 4uC. Proteins bound to beads were washed three
times with phosphate buffered saline and resuspended in 26SDS-
PAGE loading buffer. Samples were resolved by 10% SDS–PAGE
and probed with antibodies to Raf-1, PI3K, TSC2 or GST.
Results
14-3-3c induces whereas 14-3-3s suppresses
transformation of NIH3T3 and MEF cells
Studies have shown that several of the 14-3-3 genes may have
oncogenic potential when over expressed in immortalized cells or in
cancer-derived cell lines [10,20]. To our knowledge, 14-3-3 proteins
havenotbeentestedforoncogenicactivityusingthefocusformation
assay to directly test for transforming ability. Here we have focused
on the 14-3-3c isoform because we had previously shown that
elevated expression of this family member appeared to induce
genetic instability [21]. To test for oncogenic activity we utilized the
focus formation assay [22] whereby NIH3T3 or MEF cells were
transfected with an expression vector that constitutively expressed
the 14-3-3c gene. For comparison, we also transfected cells with
activated H-ras or c-myc expression vectors which are well
recognized for their oncogenic activity. In addition to these, we
also introduced 14-3-3s, because this family member is reported to
be a tumor suppressor [9]. As can be seen in figures 1A and 1B,
introduction of 14-3-3c into NIH3T3 cells resulted in the formation
of foci that are similar in number and appearance to what was
observed when c-myc was introduced into the cells, indicating that
14-3-3c can function as a transforming oncogene. Moreover, the
number of foci that occurred increased when 14-3-3c was co-
transfectedwithc-myc,suggesting14-3-3c couldcooperatewith this
Figure 1. 14-3-3c, but not 14-3-3s, induces focus formation in NIH3T3 cells. (A) H-ras, c-myc, 14-3-3c and 14-3-3s expression plasmids were
transfected into NIH3T3 cells as described in the methods section, replated 48 h after transfection and maintained for an additional 21 days.
Subsequently, the cells were stained with crystal violet and the number of foci quantified using an Oxford Optronix colony counter, UK. The
experiment was repeated twice. A typical experiment is depicted. (B) The number of foci in panel A was determined and graphed. Bars depict the
average number of foci per dish. (a, p,0.05 vs control; b, p,0.05 vs H-ras; c, p,0.05 vs c-myc, Student’s t-test). (C) Several 14-3-3c transformed foci
from the experiment in panel A were collected and tested for growth in soft agar. Twenty one days after seeding, the colonies were stained. The
growth of parental NIH3T3 cells is shown for comparison. (D) One of the clones from panel C was injected into eight SCID mice at 1610
7 cells per
injection. Tumor volume was measured every 3–4 days for a total of 25 days. For comparison, NIH3T3 cells were injected into SCID mice as a control.
doi:10.1371/journal.pone.0011433.g001
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result in more foci, indicating that 14-3-3c does not act
synergistically with H-ras, suggesting that these two oncogenes
may transform through the same mechanism. As expected, 14-3-3s
was unable to induce focus formationin this assay, butinstead could
suppress focus formation when cotransfected with either H-ras or c-
myc. The same results were observed in MEF cells (Figure S1).
To confirm the transforming ability of 14-3-3c we utilized in
vitro and in vivo assays to characterize the ability of 14-3-3c
transformed cells to grow in soft agar and form tumors in SCID
mice, respectively. Several 14-3-3c-induced foci from the exper-
iments depicted in figure 1A were expanded and expression of 14-
3-3c confirmed by immunoblotting. The cells were then tested for
anchorage independent growth on soft agar (Figure 1C). As can be
seen, the 14-3-3c transformed cells showed marked anchorage
independent growth, when compared to the control. We next
tested one of the expanded clones (clone 2) for ability to form
tumors in SCID mice. The cells were implanted subcutaneously in
SCID mice and the mice monitored for twenty five days after
implantation (Figure 1D). 14-3-3c transformed cells produced
tumors that were first measurable at about day 7 and which
continued to grow in size until termination of the experiment. No
tumors were observed in mice injected with control cells. From
these results, we conclude that 14-3-3c can act as an oncogene.
Previous studies have shown that exogenous expression of 14-3-
3b can alter the growth characteristics of cells [20]. Hence, to
further explore 14-3-3c’s transforming ability, we expressed 14-3-
3c in H358 lung cancer cell lines. For comparison, we also utilized
14-3-3s and found that while 14-3-3c did not increase
proliferation rates it did enhance anchorage independent growth
(Figures 2A and 2B). In contrast, 14-3-3s suppressed both
proliferation and anchorage independent growth of H358 cells.
Overall, our results indicate that 14-3-3c may function through
the same mechanism as H-ras in causing transformation and that
facilitating anchorage independent growth may be an important
activity of 14-3-3c oncogenic function.
MAPK and PI3K pathways are required for 14-3-3c
transformation
The lack of cooperation between 14-3-3c and H-ras suggested
that 14-3-3c may utilize the same or a parallel pathway as H-ras in
causing transformation. Consistent with this, it has been shown that
14-3-3 proteins interact with and may activate raf [23], the MAP
kinase that is stimulated by H-ras and which is essential for H-ras-
mediated transformation [24]. Recent evidence suggests that PI3K
also plays an important role in H-ras transformation[25]. Hence, to
test for involvement of MAPK and PI3K pathways in 14-3-3c
induced transformation, we used PD98059 and LY294002, which
inhibit MAPK and PI3K signaling respectively, in the transforma-
tion assay. For comparison we also suppressed p38 MAP kinase
signaling using SB203580. We first determined drug concentrations
that did not affect NIH3T3 cell viability (data not shown) but did
suppress signaling activity (Figures 3A and 3B). After transfection,
the cells were incubated with these inhibitors and focus formation
was measured after 21 days. We found that both PD98059 and
LY294002 suppressed transformation induced by H-ras (positive
control) and 14-3-3c whereas the p38 inhibitor, SB203580 showed
no effect on focus formation (Figure 3C). Collectively, these results
suggested that activation of both MAPK and PI3K signaling is
required for transformation by 14-3-3c.
14-3-3c induces activation of MAPK signaling in vivo
We next tested for activation of raf-1 signaling by 14-3-3c.
NIH3T3 cells were transfected with H-ras, 14-3-3c, or 14-3-3s
and then raf-1 tested for its ability to phosphorylate MEK
(Figures 4A and 4B). As expected, transfecting H-ras into the cells
resulted in an increased raf-1 activity as measured by its ability to
phosphorylate MEK. Similarly, transfecting 14-3-3c into the cells
also increased raf-1 activity. In contrast, there was no change in
raf-1 activity in cells transfected with 14-3-3s. To confirm these
results we immunoprecipitated 14-3-3c and 14-3-3s from
transiently transfected cells and then tested for binding with raf-
1 and for raf’s ability to phosphorylate MEK (Figure 4C). We
Figure 2. 14-3-3s, suppresses cell growth in a p53 independent
manner. (A) H358 lung cancer cells stably transfected with 14-3-3c or
14-3-3s were seeded on 35 mm dishes at 1610
3 cells per plate and the
cells cultured for 5 days. The cells in sample dishes were trypsinized and
counted every 24 h. The results from four independent experiments are
graphed. *, p,0.05 vs. control, Student’s t-test. (B) The same cell lines as
in A were tested for growth in soft agar as described in figure 1. The
average results of three independent experiments are graphed.
*, p,0.05 vs control, Student’s t-test.
doi:10.1371/journal.pone.0011433.g002
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3-3s and that the raf-1 associated with 14-3-3c could phosphor-
ylate MEK. We further examined the effects of 14-3-3 on MAPK
signaling by testing for their effects on ERK activity (Figures 4D
and 4E). Transfection of either H-ras or 14-3-3c led to a dose
dependent increase in ERK activity. However, introduction of 14-
3-3s caused a dose dependent decrease in ERK activity. Our
results indicate that 14-3-3c can stimulate MAP kinase signaling in
vivo, whereas 14-3-3s suppresses this signaling pathway.
14-3-3c activates PI3K signaling, whereas 14-3-3s inhibits it
In the above experiments we found that the LY294002 inhibitor
could suppress focus formation by 14-3-3c suggesting that
activation of PI3K signaling was important for 14-3-3c-mediated
oncogenic activity. This prompted us to test for PI3K activation in
cells that were transiently transfected with 14-3-3c or 14-3-3s
(Figures 5A and 5B). Both H-ras and 14-3-3c were potent
activators of PI3K, whereas 14-3-3s suppressed activity. This is
consistent with the concept that 14-3-3c can stimulate PI3K
signaling.
It has been shown that other 14-3-3 proteins can directly bind
components of the PI3K signaling pathway including p110-PI3K
and TSC2 [26,27]. Hence we tested for an interaction between
these two proteins and 14-3-3c and 14-3-3s. To explore this, we
created cell lines that stably expressed FLAG-tagged 14-3-3c and
14-3-3s and tested for an interaction between the 14-3-3 proteins
Figure 3. Transformation by 14-3-3c requires active MAPK and PI3Kinase pathways. NIH3T3 cells were transfected with H-ras, 14-3-3c,o r
14-3-3s plasmids and incubated for 48 hours in DMEM medium containing either 15 mM PD98059 or 5 mM LY294002. DMEM supplemented with
DMSO served as a control. After 48 h, the cells were harvested and extracts prepared and examined for the presence of phosphorylated ERK42/44 by
immunoblotting (A) or tested for PI3K activity (B) as described in the methods section. These experiments were repeated twice. A representative
figure is shown. (C) NIH3T3 focus formation assays were conducted as in figure 1 using either H-ras, 14-3-3c, 14-3-3s, or a combination of H-ras plus
14-3-3c or 14-3-3s and in media with or without 15 mM PD98059, 5 mM LY294002 or 1 mM SB202190. The assays were maintained in an incubator at
37uC and 5% CO2 for 21 days and the colonies stained and counted. The bars represent the average number of colonies per 100 mm dish from two
independent experiments. Error bars depict standard deviation. (*, p,0.05, Student’s t-test, compared with control assay conducted in the absence of
inhibitor).
doi:10.1371/journal.pone.0011433.g003
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were transiently transfected into NIH3T3 cells. Forty eight hours after transfection, the cells were serum starved overnight, harvested, and cell extracts
examined for Raf-1 activity by incubating with recombinant MEK protein in the presence of [c-
32P] ATP. Total raf-1 protein in the extracts was
determined by immunoblotting (bottom panel). The experiment was repeated three times. A typical experiment is depicted. (B) The amount of
radioactivity in the pMEK bands in panel A was quantified. Bars in the graph are the average for the three experiments. Error bars depict standard
deviation (*, p,0.05 vs. vector control). (C) Extracts were prepared from NIH3T3 cells stably transfected with FLAG-14-3-3c or FLAG-14-3-3s. 14-3-3
proteins were immunoprecipitated with anti-FLAG antibody and the precipitated proteins tested for the presence of raf-1 by immunoblotting (top
panel). Raf-1 protein was immunoprecipitated from the same extracts and tested for the presence of 14-3-3 proteins using the anti-FLAG antibody
(second panel). The extracts were also tested for raf-1 kinase activity as described above (third panel). Total 14-3-3 protein was detected in the
extracts by immunoblotting using the anti-FLAG antibody (bottom panel). (D) NIH3T3 cells were transiently transfected with increasing quantities of
H-ras, 14-3-3c, or 14-3-3s expression plasmids as indicated. Forty eight hours later the cells were harvested, extracts prepared and ERK2 activity
determined by incubating with recombinant Elk-1 protein and phosphorylated ELK detected by immunoblotting using an anti-phosphorylated-ELK
antibody. Total ERK2 protein was detected by immunoblotting using an anti-ERK2 antibody (bottom panel). The experiment was repeated three
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Immunoprecipitation of the 14-3-3 proteins followed by immu-
noblotting for p110-PI3K revealed that p110 could bind to both
14-3-3c and 14-3-3s and this was confirmed by the reciprocal
immunoprecipitation experiment. Importantly, only the p110-
PI3K bound with 14-3-3c showed catalytic activity suggesting that
14-3-3c could activate this enzyme. In contrast, when the
immunoprecipitated 14-3-3 proteins were tested for the presence
of TSC2, TSC2 was found in complex with 14-3-3c only and not
with 14-3-3s. Taken together these results indicate that 14-3-3c
and 14-3-3s have distinctly different effects on the PI3K signaling
pathway.
The above experiments suggested that the interactions between
14-3-3c and p110-PI3K and TSC2 may be important in the
stimulation of PI3K signaling. Moreover, since pharmacological
inhibition of PI3K and MAPK pathways suppressed 14-3-3c-
mediated focus formation we reasoned that the PD98059/
LY294002 inhibitors may affect the protein complexes formed
between 14-3-3c and proteins of the PI3K pathway. NIH3T3 cells
that stably expressed either 14-3-3c or 14-3-3s were treated with
LY294002 and the 14-3-3 proteins immunoprecipitated using the
FLAG antibody. For comparison, cells were also incubated with
PD98059 in a separate set of experiments (Figure 5D). As can be
seen, incubating cells with LY294002 abolished the interaction
between 14-3-3c and both p110-PI3K and TSC2. It also
eliminated coimmunoprecipitation of p110-PI3K with 14-3-3s.
PD98059 did not eliminate the interaction between the 14-3-3 and
p110-PI3K, but it did reduce the interaction with TSC2. Taken
together, our results indicate that 14-3-3c can interact with at least
two components of the PI3K signaling pathway and that this
interaction is suppressed when signaling activity through this
pathway is inhibited.
14-3-3c can stimulate PI3K activity, but not raf-1 activity,
in vitro
One of the several mechanisms that 14-3-3 proteins are thought
to act is by altering the conformation of enzymes that they interact
with causing their activation [28]. We showed that 14-3-3c could
stimulate MAPK and PI3K signaling which prompted us to test
whether 14-3-3c and 14-3-3s could alter the activity of the
signaling kinases that they interacted with. To accomplish this, we
generated 14-3-3c and 14-3-3s GST fusion proteins and purified
them from E.coli and confirmed that our recombinant proteins
could interact with raf-1, p110-PI3K, and TSC2 (Figure 6A). We
next immunopurified raf-1 from NIH3T3 cells and then added
increasing quantities of purified GST-14-3-3 proteins (Figure 6B).
Our tests for changes in basal activity showed that 14-3-3c had no
effect on raf-1 activity, indicating that direct physical interaction
between 14-3-3c and raf-1 did not modify basal raf-1 activity. As
expected, 14-3-3s had no effect on raf-1 activity since we showed
previously that it did not interact with this MAP kinase. We also
tested for the in vitro effects of adding purified 14-3-3c and 14-3-
3s to immunopurified p110-PI3K (Figure 6C). In contrast to what
we found with raf-1, 14-3-3c could stimulate p110-PI3K activity in
a dose dependent manner, whereas 14-3-3s suppressed its activity.
These results indicate that 14-3-3 proteins can modify the activity
of p110-PI3K in vitro and that 14-3-3c and 14-3-3s have
opposing effects on this kinase.
Discussion
The primary observation we have made is that 14-3-3c
functions as an oncogene and that it’s transforming activity is
mediated through activation of MAP kinase and PI3K signaling.
We previously reported that 14-3-3c is overexpressed in lung
cancer [13] implying that this 14-3-3 family member has
oncogenic potential. In this study, we found that the overexpres-
sion of 14-3-3c in NIH3T3 or MEF cells resulted in focus
formation. These transformed cells exhibited anchorage-indepen-
dent growth in soft agar and tumor formation in SCID mice, both
hallmarks of the transformed phenotype. Importantly, we show
that overexpression of 14-3-3c leads to constitutive activation of
the MAPK and PI3K pathways. Similarly, Takihara, et al. [20]
reported that increased MAPK signaling activity was observed in
the 14-3-3b transformed cells. Since increased activation of
MAPK and PI3K pathways can result in malignant transforma-
tion [29,30], we suppressed ERK/PI3K activation with
PD98059/LY294002 inhibitors and found that inhibition of either
signaling pathway decreased foci formation by 14-3-3c. This
suggests that the concerted action of both pathways is essential for
transformation by this oncogene.
Our co-immunoprecipitation experiments showed that 14-3-3c
interacts with Raf-1 and this was also confirmed in vitro GST
binding assays. Interestingly, Raf-1 kinase activity could be
stimulated by 14-3-3c in vivo but not in vitro where we utilized
purified protein. Activation of Raf-1 is a complex event that
requires multiple accessory proteins that were not present in our in
vitro experiment. Hence, 14-3-3c alone could not activate Raf-1 in
vitro. This is consistent with previous study carried out by [31],
where they showed that Raf-1 could not be activated by purified
GST-14-3-3e recombinant protein. However, overexpression of
14-3-3c did lead to increased Raf-1 activity in vivo and this could
be explained by several ways. 14-3-3c may stabilize the
conformation required for substrate recognition and catalytic
activity or may mediate the interaction of Raf-1 with other
downstream signaling molecules. Another possibility is that 14-3-
3c could facilitate the intracellular trafficking involved in the
translocation of Raf-1 where it becomes activated.
Studies have shown that 14-3-3 proteins play an important role
in the PI3K-Akt signaling pathway by interacting with TSC2
protein [32,33,34]. This interaction is phosphorylation-dependent,
requiring TSC2 phosphorylation on S939 and S981 by AKT [27].
This prompted us to study the interaction of 14-3-3 and TSC2
proteins by immunoprecipitation and we found that TSC2 binds
to 14-3-3c protein both in vivo and in vitro. TSC2 is a critical
mediator of both MAPK and PI3K pathways [35,36,37,38], hence
we tested whether the interaction between 14-3-3c and TSC2 was
affected by the presence of PD98059/LY294002 inhibitors. We
observed that both these inhibitors strongly reduced the
interaction of 14-3-3c with TSC2. This is in conjunction with
the suppression of focus formation in the presence of PD98059/
LY294002 inhibitors, suggested that transformation by 14-3-3c
requires interaction with TSC2 and activation of mTOR.
14-3-3s is down regulated by promoter methylation or
ubiquitin-mediated degradation [39,40] and acts as a tumor
suppressor. Our study confirmed this in co-transfection studies
with H-ras and c-myc, wherein 14-3-3s markedly reduced the
transformation induced by H-ras in NIH3T3 cells. We also
times. A typical experiment is depicted. (E) The density of the bands in panel D was quantified using Image J (NIH, MD). Bars in the graph are the
average of the three experiments. Error bars depict standard deviation (*, p,0.05 vs. control, Student’s t-test).
doi:10.1371/journal.pone.0011433.g004
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PLoS ONE | www.plosone.org 7 July 2010 | Volume 5 | Issue 7 | e11433Figure 5. 14-3-3cstimulates PI3K activity. (A)IncreasingquantitiesofH-ras,14-3-3cand14-3-3sexpressionplasmids weretransientlytransfectedinto
NIH3T3 cells. Forty eight hours later the cells were serum starved overnight and then the cells harvested. The PI3K-p110 catalytic subunit was
immunoprecipated and catalytic activity measured by incubating with phosphatidyl inositol and [c-
32P] ATP. Radiolabled phosphatidyl inositol was
detectedusing thin layer chromatography (Top panel).Parallel aliquotsof thesameprecipitates wereresolved by SDS-PAGEand immunoblottedwith anti-
p110 antibody (bottompanel). Theexperiment was repeatedthreetimes. Atypical result is depicted.(B)Radioactivity inthe PI (3)-P spotsfrompanelAw a s
quantified. Bars in the graph are the average of the three experiments. Error bars depict standard deviation (*, p,0.05 vs. control, Student’s t-test). (C)
Extracts from NIH3T3 cells stably expressing FLAG-14-3-3c or FLAG-14-3-3s were prepared. 14-3-3 proteins were immunoprecipitated using an anti-FLAG
antibody and probed for the presence of PI-3 kinase using an anti-p110 antibody (top panel). PI-3 kinase p110 subunit was immunoprecipitated and the
precipitated proteins probed for the presence of 14-3-3 using an anti-FLAG antibody (second panel). PI3K activity was detected in the FLAG antibody
immunoprecipitates by incubating with phosphatidyl inositol as described previously (third panel from the top). 14-3-3 proteins were immunoprecipitated
withthe anti-FLAG antibody andtheimmunoprecipitatedproteins probedforthe presenceof TSC2 by immunoblottingwithananti-TSC2 antibody (fourth
panel from the top). TSC2 protein was immunoprecipitated from the extracts and the precipitated proteins probed for the presence of 14-3-3 proteins by
immunoblotting with the anti-FLAG antibody. Total 14-3-3 protein in the extracts was detected by immunoblotting with the anti-FLAG antibody. An IgG
controlisshownforcomparison.(D)14-3-3cand14-3-3sstablyexpressingcellsweretreatedwitheitherPD98059orLY294002asindicated.14-3-3proteins
were immunoprecipitated with an anti-FLAG antibody and the immunoprecipitated proteins probed for PI-3 kinase by immunoblotting with an anti-p110
antibody (top panel). In a parallel experiment, the FLAG antibody immunoprecipitated proteins were probed for the presence of TSC2 (second panel).
Finally,theextractswereprobedfortotallevelofTSC2(thirdpanel),PI-3kinasep110subunit(fourthpanelfromthetop),and14-3-3protein(bottompanel)
by immunoblotting with the appropriate antibody. Proteins immunoprecipitated using an IgG control are shown for comparison.
doi:10.1371/journal.pone.0011433.g005
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cells. Previously, Yang et al. [41] showed that 14-3-3s binds to
AKT and inactivates its function and, since both AKT and PI3K
lie in the same pathway; it is possible that 14-3-3s might block
both these enzyme activities simultaneously. Hence 14-3-3s may
function as a tumor suppressor by inhibiting the same pathways
that are activated by 14-3-3c. Therefore; 14-3-3c and 14-3-3s
have opposing biological activities.
In conclusion, the results presented in this report show that
activation of MAPK and PI3K pathways are essential for 14-3-3c
induced transformation. Furthermore, suppression of these
pathways by 14-3-3s could be one of the mechanisms of its
tumor suppressor function. A critical question, however, is how
these proteins function differently even though they share more
than 85% homology in their structure. We are currently
investigating the transforming ability and tumor suppressor
function of these proteins.
Supporting Information
Figure S1 Transformation assay in MEF cells. H-ras and 14-3-3
expression plasmids were transfected into MEF cells as described
in ‘‘Materials and Methods.’’ Transformed foci were stained with
crystal violet.
Found at: doi:10.1371/journal.pone.0011433.s001 (0.19 MB TIF)
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